Metabolic hormones and breast cancer risk among Mexican American Women in the Mano a Mano Cohort Study.
Age Factors
Breast Neoplasms
/ blood
C-Peptide
/ blood
Case-Control Studies
Chemokine CCL2
/ blood
Female
Gastric Inhibitory Polypeptide
/ blood
Humans
Insulin
/ blood
Leptin
/ blood
Mexican Americans
/ statistics & numerical data
Pancreatic Polypeptide
/ blood
Peptide YY
/ blood
Prospective Studies
Risk Factors
United States
/ epidemiology
Up-Regulation
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 07 2019
10 07 2019
Historique:
received:
21
03
2019
accepted:
23
06
2019
entrez:
12
7
2019
pubmed:
12
7
2019
medline:
21
10
2020
Statut:
epublish
Résumé
C-peptide, insulin, leptin, and other metabolic hormones are assumed to play roles in breast cancer development; though, results are inconsistent. In this prospective case-control study nested within the Mano a Mano Cohort Study, we assessed the risk of breast cancer with regard to plasma levels of c-peptide, gastric inhibitory polypeptide, insulin, leptin, monocyte chemoattractant protein-1, pancreatic polypeptide, and peptide YY. Among women followed for a median of 8.5 years, 109 breast cancer cases were identified and frequency-matched to 327 controls at a ratio of 1:3. Overall, only c-peptide was observed significantly associated with breast cancer risk. High c-peptide levels (≥ the median level of controls) were significantly associated with increased breast cancer risk (odds ratio [OR] = 1.39, 95% confidence interval [CI]: 1.01, 2.44). In an analysis of participants stratified by age, the significant association between c-peptide levels and breast cancer risk was evident in only women age ≥51 years (OR = 1.53, 95% CI: 1.02, 3.27). Among women age <51 years, high leptin levels were significantly associated with decreased breast cancer risk (OR = 0.49, 95% CI: 0.24, 0.82). Our findings suggest that selected metabolic hormones are associated with breast cancer development in Mexican American women.
Identifiants
pubmed: 31292496
doi: 10.1038/s41598-019-46429-9
pii: 10.1038/s41598-019-46429-9
pmc: PMC6620309
doi:
Substances chimiques
C-Peptide
0
CCL2 protein, human
0
Chemokine CCL2
0
Insulin
0
LEP protein, human
0
Leptin
0
Peptide YY
106388-42-5
Gastric Inhibitory Polypeptide
59392-49-3
Pancreatic Polypeptide
59763-91-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9989Subventions
Organisme : NCI NIH HHS
ID : P20 CA221696
Pays : United States
Références
Cancer Causes Control. 2000 Sep;11(8):721-30
pubmed: 11065009
Int J Breast Cancer. 2014;2014:189384
pubmed: 25653879
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Surgery. 2013 Dec;154(6):1206-13; discussion 1214
pubmed: 24238043
Sci Rep. 2015 Nov 24;5:17221
pubmed: 26596774
Sci Rep. 2017 Oct 5;7(1):12708
pubmed: 28983080
Crit Rev Clin Lab Sci. 1984;19(4):297-352
pubmed: 6373142
J Physiol. 2009 Jan 15;587(1):19-25
pubmed: 19064614
Diabetes Res Clin Pract. 1997 Jun;36(3):173-80
pubmed: 9237784
Cancer Res. 1992 Jul 15;52(14):3924-30
pubmed: 1617668
Diabetologia. 2003 Jun;46(6):798-801
pubmed: 12764578
Diabetes. 2004 Dec;53(12):3091-6
pubmed: 15561938
J Endocrinol Invest. 1997 Oct;20(9):531-6
pubmed: 9413807
CA Cancer J Clin. 2017 Sep;67(5):378-397
pubmed: 28763097
J Biol Chem. 2003 Aug 1;278(31):28668-76
pubmed: 12734209
Int J Cancer. 2006 Aug 1;119(3):659-67
pubmed: 16572422
Eur J Cancer. 2011 Jan;47(1):33-43
pubmed: 20889333
J Endocrinol. 1990 Feb;124(2):R1-3
pubmed: 1690256
PLoS One. 2015 Jun 01;10(6):e0128891
pubmed: 26030767
Eur Rev Med Pharmacol Sci. 2002 Mar-Jun;6(2-3):55-9
pubmed: 12708611
Novartis Found Symp. 2004;262:84-98; discussion 98-107, 265-8
pubmed: 15562824
JAMA Oncol. 2015 Aug;1(5):611-21
pubmed: 26182172
Int J Cancer. 1992 Oct 21;52(4):511-6
pubmed: 1399128
Proc Nutr Soc. 2008 Aug;67(3):253-6
pubmed: 18452640
Cancer Res. 2001 Jun 1;61(11):4636-41
pubmed: 11389101
Int J Cancer. 2009 Jan 15;124(2):402-11
pubmed: 18798278
Breast Cancer Res. 2012 May 14;14(3):R76
pubmed: 22583394
Cancer Causes Control. 2013 May;24(5):873-83
pubmed: 23408243
Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):161-4
pubmed: 17220346
Prev Chronic Dis. 2017 Mar 16;14:E24
pubmed: 28301314
Int J Mol Epidemiol Genet. 2013 Sep 12;4(3):156-66
pubmed: 24046808
J Clin Endocrinol Metab. 1996 Apr;81(4):1460-4
pubmed: 8636351
Int J Obes (Lond). 2016 May;40(5):761-7
pubmed: 26620887
Ann Intern Med. 2010 Jan 19;152(2):93-100
pubmed: 20083828
Arch Gynecol Obstet. 2011 Nov;284(5):1271-6
pubmed: 21249376
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Curr Breast Cancer Rep. 2011 Sep;3(3):142-150
pubmed: 21949568
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1786-96
pubmed: 24097198
Int J Epidemiol. 2017 Apr 1;46(2):e3
pubmed: 25747868
Cancer Prev Res (Phila). 2011 Sep;4(9):1449-56
pubmed: 21680707
Breast Cancer Res Treat. 2019 Feb;174(1):209-218
pubmed: 30465158
Cancers (Basel). 2018 Sep 01;10(9):
pubmed: 30200454
Breast Cancer Res Treat. 2006 Jul;98(2):157-65
pubmed: 16502016
Breast Cancer Res Treat. 2018 Aug;170(3):477-486
pubmed: 29594759
Semin Reprod Med. 2002 May;20(2):103-12
pubmed: 12087495
BMJ Open Sport Exerc Med. 2017 Mar 1;2(1):e000143
pubmed: 28879026